

Yotam Bronstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10120109/publications.pdf>

Version: 2024-02-01

11
papers

677
citations

1477746

6
h-index

1588620

8
g-index

11
all docs

11
docs citations

11
times ranked

1710
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173. | 0.6 | 539 |
| 2 | Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 341. | 3.8 | 76 |
| 3 | Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. <i>Journal of Medical Virology</i> , 2022, 94, 1241-1245. | 2.5 | 22 |
| 4 | Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 148-151. | 2.5 | 15 |
| 5 | COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge. <i>Cancer Cell</i> , 2022, 40, 578-580. | 7.7 | 12 |
| 6 | Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. <i>Frontiers in Oncology</i> , 2021, 11, 646971. | 1.3 | 7 |
| 7 | REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection. <i>EJHaem</i> , 2022, 3, 471-474. | 0.4 | 4 |
| 8 | Hemato-oncology Tourism in Israel: A Retrospective Review. <i>JCO Global Oncology</i> , 2020, 6, 1314-1320. | 0.8 | 2 |
| 9 | Presence of α ACKR1/DARC null polymorphism in Arabs from Jisr az-Zarqa with benign ethnic neutropenia. <i>Pediatric Research</i> , 2021, , . | 1.1 | 0 |
| 10 | Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021, 138, 2641-2641. | 0.6 | 0 |
| 11 | The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective. <i>Blood</i> , 2021, 138, 4686-4686. | 0.6 | 0 |